Evidence map›Paper›PMID 35178159›Full record

ArticleOxidative medicine and cellular longevity2022

Serum Pharmacochemistry Combining Network Pharmacology to Discover the Active Constituents and Effect of Xijiao Dihuang Tang Prescription for Treatment of Blood-Heat and Blood-Stasis Syndrome-Related Disease.

Yuxin Chen, Yang Dai, Jie Xia, Jing Liu, Guisheng Zhou, Cuihua Chen, Baoping Jiang, Lian Yin, Guochun Li

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuxin ChenSchool of Pharmacy, Nanjing University of Chinese Medicine, 210046 Nanjing, China.
Yang DaiSchool of Pharmacy, Nanjing University of Chinese Medicine, 210046 Nanjing, China.
Jie XiaSchool of Pharmacy, Nanjing University of Chinese Medicine, 210046 Nanjing, China.
Jing LiuSchool of Pharmacy, Nanjing University of Chinese Medicine, 210046 Nanjing, China.
Guisheng ZhouSchool of Pharmacy, Nanjing University of Chinese Medicine, 210046 Nanjing, China.
Cuihua ChenSchool of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, 210046 Nanjing, China.
Baoping JiangSchool of Pharmacy, Nanjing University of Chinese Medicine, 210046 Nanjing, China.
Lian YinSchool of Pharmacy, Nanjing University of Chinese Medicine, 210046 Nanjing, China.ORCID https://orcid.org/0000-0002-3212-7386
Guochun LiSchool of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, 210046 Nanjing, China.ORCID https://orcid.org/0000-0002-1680-130X
Nanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xijiao Dihuang Tang (XDT), a classic TCM prescription, has been used to clinically treat blood-heat and blood-stasis syndrome- (BHSS-) related diseases, including hemorrhagic stroke and sepsis. However, the active constituents and mechanism of XDT in the treatment of BHSS-related diseases have not been elucidated due to the lack of appropriate methodologies. In this study, serum pharmacochemistry and network pharmacology were used to explore the active constituents and the mechanism of XDT in the treatment of BHSS-related diseases. The effects of XDT were evaluated using dry yeast-induced rats as rat models with BHSS, which demonstrated the antipyretic and anticoagulant properties of XDT. The HPLC-QTOF/MS/MS assay was used to identify 60 serum constituents of XDT (SCXDT). Then, 338 targets of 60 SCXDT were predicted by integrating multiple databases and the MACCS fingerprint similarity prediction method. The degree of topological properties with targets of 19 key active constituents in SCXDT was identified and evaluated in glutamate-induced PC12 cells. Subsequently, 338 targets of 60 SCXDT were mainly involved in biological processes such as inflammation, coagulation, cell proliferation, and apoptosis, as well as oxidative contingencies via compound-target-disease network analysis. The core targets including IL-1

Indexed as

AnimalsDrugs, Chinese HerbalHematologic DiseasesHemorrhagic StrokeHumansMaleNetwork PharmacologyRatsRats, Sprague-DawleySepsisDrugs, Chinese Herbal

Identifiers

PMID35178159
PMCPMC8845118
OpenAlexW4210841924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.